GODAVARIBNSEGODAVARI BIOREFINERIES LMediumNeutral
Announced Thu, 13 Aug · 18:10 IST

Q1 FY27 earnings call transcript filed, bio-chemicals revenue up 19 percent

Mgmt Guided Margin ImprovementMgmt Guided Margin PressureOrder Pipeline DisclosedInvestor Communications View source PDFExplain this filing

GODAVARIB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.0%1-day move
₹254.00
prior close
₹254.60
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.3+0.2+0.2-3.0-1.6-2.9-2.8-4.0
Up moveDown movePending
AI summary

Q1 FY27 revenue INR557.9 cr, up 4.6 percent YoY. Net loss INR19.3 cr versus INR16 cr last year. Bio-based chemicals strong: revenue up 19.4 percent to INR168.7 cr, EBITDA up 53 percent to INR19.2 cr, margin at 11.4 percent. Sugar-ethanol segment weak with EBITDA loss of INR14.6 cr. Commissioned 200 KLPD grain distillery, total capacity 800 KLPD. Plans INR25 cr debottlenecking in bio-chemicals, targeting INR240 cr per quarter. DME pilot results expected March 2027. CDSCO application filed for TNBC drug trial.

Likely market impact

Bio-chemicals margin expansion is positive, but consolidated loss widens. Capacity additions and drug trial progress support long-term growth.